Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11211705 | 0.91 | ALDH1A1 (0.35) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL3062956 | 0.85 | ALDH1A1 (0.38) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL1033008 | 0.85 | ALDH1A1 (0.38) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| Methane SCHEMBL28218821 | 0.83 | ALDH1A1 (0.37) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL548963 | 0.83 | ALDH1A1 (0.36) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL16054795 | 0.83 | ALDH1A1 (0.37) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL9307815 | 0.83 | MEN1 (0.31) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL1031267 | 0.80 | FFAR3 (0.38) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL9025615 | 0.79 | ALDH1A1 (0.34) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL21269721 | 0.78 | FFAR3 (0.36) | ALDH1A1MEN1CYP1A2THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2731941-B1 | NOVEL AND SELECTIVE CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2019-05-08 | — | — | EP | disclosed |
| US-9108958-B2 | Selective CCR2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-18 | — | — | US | disclosed |
| EP-2571870-B1 | CCR2 ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2015-01-21 | — | — | EP | disclosed |
| EP-2802592-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8841313-B2 | CCR2 antagonists and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-23 | — | — | US | disclosed |
| WO-2013104703-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-07-18 | — | — | WO | disclosed |
| US-20130184299-A1 | CCR2 ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130172348-A1 | NOVEL AND SELECTIVE CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| EP-2571870-A1 | CCR2 ANTAGONISTS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011144501-A1 | CCR2 ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | WO | disclosed |
| US-4308384-A | Production of triazinones | GLAXO GROUP LIMITED (GB) | 1981-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172348-A1 | NOVEL AND SELECTIVE CCR2 ANTAGONISTS | CCR2, CXCR2, CCRL2 | ALDH1A1 2518/4885MEN1 4880/4885CYP1A2 1119/4885 |
| US-20130184299-A1 | CCR2 ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCL2 | ALDH1A1 1753/4885MEN1 4859/4885CYP1A2 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.